drugset
drugset / Trial / NCT00554983

Efficacy and Safety From a Recombinant Folding Variant of Bet v 1

NCT00554983 ↗

Phase 3 Completed 255 enrolled Allergopharma GmbH & Co. KG
RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and Safety from a recombinant folding variant of Bet v 1

Timeline

Start
2007-09
Primary completion
2010-06
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject rBet v1-FV Protein / enzyme biologic 80 ug Subcutaneous

Indications

allergic disease